DarioHealth Partners With a Leading Diabetes Clinic
Plans to Onboard the Clinic's 5,000 Patients as Dario Users
Feb 12, 2018
NEW YORK and CAESAREA, Israel, Feb. 12, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced it has partnered with the Diabetes and Endocrinology Consultants of Pennsylvania, LLC, the clinical practice of Dr. Alan Schorr and Dr. Arvind Cavale, with expertise in incorporating state of the art technology in the treatment of people with Type 1 and Type 2 diabetes.
With this market expansion, the Dario™ Blood Glucose Monitoring System will be offered in their clinic, which provides a wide-range of treatment therapies for over 5,000 patients. The product was chosen because it is compact, accurate, and it has the ability for users and healthcare practitioners to simplify diabetes management via a smartphone.
Dr. Alan Schorr, of Diabetes and Endocrinology Consultants of Pennsylvania, LLC, said: "When I showed my patients how to use Dario, they immediately got it and I realized that this was going to be a game-changing device."
"The Dario system provides patients with a platform to control their blood sugars in an easy and concise manner. The patient's sugars and essential data is easy to understand, and patients are coming to the office more informed. My team is able to interpret the data and teach our patients to improve their control of diabetes. This is done in part because Dario simplifies the complexity of diabetes treatment and improves the quality of life for my patients. The device is easy to maintain and does not require carrying multiple items, which is a major plus."
Dr. Arvind Cavale, of Diabetes and Endocrinology Consultants of Pennsylvania LLC, commented: "We are excited that Dario technology will help us seamlessly incorporate remote blood glucose monitoring into our daily clinical processes, thereby allowing us to actively identify and manage those patients with diabetes that need our guidance in a timely manner. We hope to demonstrate with this project that clinicians and technology companies can bring high-value services to the management of chronic illnesses such as diabetes."
Erez Raphael, Chairman and CEO of DarioHealth, commented: "It's very encouraging to hear from endocrinologists that people with diabetes can get better care with Dario. This is an important step in DarioHealth's growth and market penetration as we are planning to reach additional users through key opinion leaders and clinics. Partnering with such clinics will allow us to reach users in a faster and a more efficient manner."
The Dario Blood Glucose Monitoring System syncs with the acclaimed Dario Smart Diabetes Management app, which is available in the App Store and Google Play Store. With the device, the app can measure, record and track blood glucose levels. In addition, the app can record carb intake, insulin medication, physical activity, and comes complete with a weight log that lets users track their weight over time.
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease treatment, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel. For more information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes that it plans to subscribe the Diabetes and Endocrinology Consultants of Pennsylvania, LLC's 5,000 patients as users, when it discuss reaching additional users, through key opinion leaders and clinics, and when it discusses its growth plans and strategies, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact: Shmuel Herschberg, Marketing Director, email@example.com, 1-914-775-5548
DarioHealth Public Relations Contact: Terese Kelly, Rosica PR, firstname.lastname@example.org, 1-201-843-5600
DarioHealth Investor Relations Contact: Westwicke Partners, Dario@Westwicke.com, 1-443-213-0500
SOURCE DarioHealth Corp.